Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model

OBJECTIVES: STM-001, a retargeted glycopeptide, is active against MDR E. coli expressing ESBLs including carbapenemases. Herein, we assessed its capability to combat E. coli complicated urinary tract infections (cUTI) in mice driven by clinically important serine (CTX-M-15) and metallo-β-lactamases...

Descripción completa

Detalles Bibliográficos
Autores principales: Neville, Lewis F., Shalit, Itamar, Warn, Peter A., Rendell, Jacob T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155633/
https://www.ncbi.nlm.nih.gov/pubmed/35229156
http://dx.doi.org/10.1093/jac/dkac063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155633/
https://www.ncbi.nlm.nih.gov/pubmed/35229156
http://dx.doi.org/10.1093/jac/dkac063

Ejemplares similares